Firas Aubeid, MD
Internal Medicine · New Lenox, ILNPI 1760771968
Payments from drug & device makers
Across 264 payments — averaging $26.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- AstraZeneca$763
- Novo Nordisk$752
- Pfizer$468
- Bayer$426
- Lilly USA, LLC$396
- plus $3K from 26 others
What the payments were for
- Travel & lodging$84912%
- Food & beverage$6,15688%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 12 | $1,338 |
| AstraZeneca | 20 | $763 |
| Novo Nordisk | 43 | $752 |
| Pfizer | 29 | $468 |
| Bayer | 14 | $426 |
| Lilly USA, LLC | 22 | $396 |
| Merck | 18 | $360 |
| GSK | 19 | $335 |
| Gilead | 11 | $335 |
| Novartis | 12 | $192 |
| Otsuka America Pharmaceutical, Inc. | 8 | $184 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $182 |
| AbbVie | 9 | $168 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $153 |
| Intuitive Surgical | 1 | $133 |
| E.r. Squibb & Sons, L.L.C. | 5 | $108 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $95 |
| Cequr Corporation | 1 | $94 |
| Kowa Pharmaceuticals America, Inc. | 1 | $85 |
| Johnson & Johnson | 3 | $77 |
| Exact Sciences | 3 | $55 |
| Mylan Specialty L.p. | 3 | $49 |
| Amgen | 3 | $45 |
| Amarin Pharma, Inc. | 3 | $44 |
| Dexcom, Inc. | 1 | $33 |
| Edwards Lifesciences | 2 | $32 |
| Radius Health, Inc. | 1 | $27 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Abbott | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaSeal$907
- BREZTRI$218
- AIRSUPRA$162
- FARXIGA$162
- Da Vinci Surgical System$133
- NURTEC ODT$125
- Kerendia$123
- Vemlidy$108
How this compares
$7,005 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 324 | $166,665 |
| OzempicSemaglutide | 49 | $80,684 |
| JardianceEmpagliflozin | 42 | $58,317 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $54,472 |
| FarxigaDapagliflozin Propanediol | 51 | $48,207 |
| XareltoRivaroxaban | 61 | $36,540 |
| JanuviaSitagliptin Phosphate | 65 | $35,969 |
| MounjaroTirzepatide | 32 | $35,236 |
| PrezcobixDarunavir/Cobicistat | 12 | $29,778 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $26,454 |
| EntrestoSacubitril/Valsartan | 31 | $23,008 |
| LinzessLinaclotide | 26 | $22,238 |
| NexletolBempedoic Acid | 14 | $14,767 |
| Atorvastatin Calcium | 1,148 | $10,931 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $10,049 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $468 | $166,665324 claims |
| Novo NordiskOzempic | $752 | $80,68449 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $763 | $74,66184 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $335 | $69,61889 claims |
| Johnson & JohnsonXarelto, Prezcobix | $77 | $66,31873 claims |
| MerckJanuvia | $360 | $35,96965 claims |
| Lilly USA, LLCMounjaro | $396 | $35,23632 claims |
| NovartisEntresto | $192 | $23,00831 claims |
| AbbVieLinzess | $168 | $22,23826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in New Lenox
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.